PTC Therapeutics PTCT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $272.55M-76.8% | $164.68M-22.7% | $211.01M+7.2% | $178.88M-4.2% | $1.18B+460% | ||
| $100.87M-7.4% | $133.13M+6.7% | $100.16M-37.9% | $112.99M-14.5% | $108.97M-6.2% | ||
| $86.18M+6.5% | $96.87M+14.4% | $84.05M+14.4% | $85.26M+22.7% | $80.96M+10.5% | ||
| $11.58M+205% | $9.35M+183% | $7.53M+148% | $4.06M+41.7% | $3.8M-92.6% | ||
| $227.59M+10.6% | $236.03M-37.2% | $207.99M-17.2% | $213.83M-5.8% | $205.87M-19.4% | ||
| $227.59M+10.6% | $236.03M-37.2% | $207.99M-17.2% | $213.83M-5.8% | $205.87M-19.4% | ||
| $44.96M-95.4% | $0+100% | $3.02M+106% | -$34.96M+13.1% | $970.23M+2,235% | ||
| 16.5%-66.0pp | 0%+76.2pp | 1.4%+29.1pp | -19.5%+2.0pp | 82.5%+104pp | ||
| -$49.03M-43.8% | -$55.19M-34.4% | -$32.59M+21.7% | -$30.36M+30.2% | -$34.09M+16.5% | ||
| $1.61M+126% | -$12.55M-242% | $6.5M+447% | -$5.74M-183% | -$6.31M-496% | ||
| -$2.46M-100% | —— | -$23.07M+76.5% | -$71.05M+17.1% | $929.83M+1,198% | ||
| $347K-99.5% | —— | -$38.97M-550% | -$6.2M-146% | $63.27M+820% | ||
| -$2.81M-100% | —— | $15.9M+115% | -$64.85M+34.6% | $866.56M+1,046% | ||
| -1%-74.7pp | —— | 7.5%+61.7pp | -36.3%+16.9pp | 73.7%+117pp | ||
| -$0.03-100% | —— | $0.20+114% | -$0.83+35.7% | $10.04+937% | ||
| -$0.03-100% | —— | $0.20+114% | -$0.83+35.7% | $11.09+1,024% | ||
| 82.5M-4.5% | 88.3M+14.9% | 87.1M+13.2% | 78.2M+1.9% | 86.4M+12.9% | ||
| 82.5M+5.6% | 79.5M+3.5% | 78.5M+2.0% | 78.2M+1.9% | 78.1M+2.1% | ||
| $28.03M+118% | $6.95M-57.3% | $15.78M+45.5% | $11.42M-26.5% | $12.86M-12.7% | ||
| -$927K-1,104% | $10.28M— | -$472K+74.4% | -$99K+94.4% | -$77K— | ||
| -$49.03M-43.8% | -$55.19M-34.4% | -$32.59M+21.7% | -$30.36M+30.2% | -$34.09M+16.5% | ||
| $11.58M+205% | $9.35M+183% | $7.53M+148% | $4.06M+41.7% | $3.8M-92.6% | ||
| —— | —— | —— | —— | $800K+700% | ||
| —— | —— | —— | —— | —— | ||
| $1.61M+126% | -$12.55M-242% | $6.5M+447% | -$5.74M-183% | -$6.31M-496% | ||
| $272.55M-76.8% | $164.68M-22.7% | $211.01M+7.2% | $178.88M-4.2% | $1.18B+460% | ||
| $44.96M-95.4% | $0+100% | $3.02M+106% | -$34.96M+13.1% | $970.23M+2,235% | ||
| $60.37M-93.8% | $12.9M+108% | $14.13M+129% | -$27.37M+17.5% | $977.45M+9,731% | ||
| $60.37M-93.8% | $12.9M+108% | $14.13M+129% | -$27.37M+17.5% | $977.45M+9,731% | ||
| 22.2%-61.0pp | 7.8%+80.8pp | 6.7%+31.1pp | -15.3%+2.5pp | 83.1%+78.4pp | ||
| $44.96M-95.4% | $0+100% | $3.02M+106% | -$34.96M+13.1% | $970.23M+2,235% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is PTC Therapeutics's revenue?
- PTC Therapeutics (PTCT) generated $827.1M in revenue over the trailing twelve months, down 53.3% year over year.
- Is PTC Therapeutics profitable?
- PTC Therapeutics reported $814.8M in net income over the trailing twelve months, a 42.3% net margin.
- What are PTC Therapeutics's profit margins?
- Gross margin is 96.0% and operating margin is 1.6%, with a 42.3% net margin.
- What is PTC Therapeutics's earnings per share?
- PTC Therapeutics's diluted EPS over the trailing twelve months is $9.38.
- Where does PTC Therapeutics's income statement data come from?
- Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
